Float Short %

9.56

Margin Of Safety %

Put/Call OI Ratio

0.49

EPS Next Q Diff

-0.02

EPS Last/This Y

0.35

EPS This/Next Y

1.14

Price

4.95

Target Price

9.6

Analyst Recom

Performance Q

-14.06

Relative Volume

1.65

Beta

0.85

Ticker: ALDX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	ALDX	5.13	0.33	7.30	28422
2025-11-11	ALDX	5.23	0.34	0.26	28687
2025-11-12	ALDX	5.3	0.33	5.78	29284
2025-11-13	ALDX	5.03	0.31	0.03	28930
2025-11-14	ALDX	5.06	0.30	0.07	29600
2025-11-17	ALDX	4.95	0.30	0.39	29662
2025-11-18	ALDX	4.91	0.30	0.58	30026
2025-11-19	ALDX	4.86	0.30	0.66	30093
2025-11-20	ALDX	4.72	0.30	0.24	30219
2025-11-21	ALDX	4.95	0.31	1.74	30348
2025-11-24	ALDX	5.23	0.33	1.80	30703
2025-11-25	ALDX	5.26	0.34	0.31	31323
2025-11-26	ALDX	5.59	0.34	0.32	31541
2025-12-01	ALDX	5.22	0.34	4.99	32100
2025-12-02	ALDX	4.86	0.38	1.72	33413
2025-12-03	ALDX	4.87	0.47	2.41	37309
2025-12-04	ALDX	4.87	0.49	0.42	38667
2025-12-05	ALDX	4.7	0.48	1.02	40800
2025-12-08	ALDX	4.96	0.49	0.48	41879
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	ALDX	5.13	34.3	-	-0.66
2025-11-11	ALDX	5.23	34.3	-	-0.66
2025-11-12	ALDX	5.31	34.3	-	-0.66
2025-11-13	ALDX	5.03	34.3	-	-0.66
2025-11-14	ALDX	5.06	34.3	-	-0.66
2025-11-17	ALDX	4.96	34.3	-	-0.66
2025-11-18	ALDX	4.91	34.3	-	-0.58
2025-11-19	ALDX	4.86	34.3	-	-0.58
2025-11-20	ALDX	4.74	34.3	-	-0.58
2025-11-21	ALDX	4.96	48.2	-	-0.59
2025-11-24	ALDX	5.23	48.2	-	-0.59
2025-11-25	ALDX	5.26	48.2	-	-0.59
2025-11-26	ALDX	5.59	48.2	-	-0.59
2025-12-01	ALDX	5.25	48.2	-	-0.59
2025-12-02	ALDX	4.87	48.2	-	-0.59
2025-12-03	ALDX	4.87	48.2	-	-0.59
2025-12-04	ALDX	4.87	48.2	-	-0.59
2025-12-05	ALDX	4.70	48.2	-	-0.59
2025-12-08	ALDX	4.95	48.2	-	-0.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	ALDX	-0.99	1.73	8.04
2025-11-11	ALDX	-0.99	1.73	8.04
2025-11-12	ALDX	-0.99	1.73	9.11
2025-11-13	ALDX	-0.99	1.73	9.11
2025-11-14	ALDX	-0.99	1.73	9.11
2025-11-17	ALDX	-0.99	5.15	9.11
2025-11-18	ALDX	-0.99	5.15	9.11
2025-11-19	ALDX	-0.99	5.15	9.11
2025-11-20	ALDX	-0.99	5.15	9.11
2025-11-21	ALDX	-0.99	5.15	9.11
2025-11-24	ALDX	-0.99	7.44	9.11
2025-11-25	ALDX	-0.99	7.44	9.11
2025-11-26	ALDX	-0.99	7.44	9.56
2025-12-01	ALDX	-0.99	7.42	9.56
2025-12-02	ALDX	-0.99	7.42	9.56
2025-12-03	ALDX	-0.99	7.42	9.56
2025-12-04	ALDX	-0.99	7.42	9.56
2025-12-05	ALDX	-0.99	7.42	9.56
2025-12-08	ALDX	-0.99	7.36	9.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

-0.99

Institutional Transactions

7.36

Beta

0.85

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-90.4

Target Price

9.6

P/E

Forward P/E

PEG

P/S

P/B

6.05

P/Free Cash Flow

EPS

-0.72

Average EPS Est. Cur. Y

-0.59

EPS Next Y. (Est.)

0.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.65

Return on Equity vs Sector %

-114.6

Return on Equity vs Industry %

-99.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

Aldeyra Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 8

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today

news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance

stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market

stock prices ALDX premarket after hours

ticker ALDX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y